Emergency
Department Use

Consider DSUVIA for your adult patients
who require an opioid analgesic for acute pain

Please see Indications and Usage, Limitations of Use, and Important Safety Information, including BOXED WARNING, below.

Effective pain relief, efficiently delivered.^1-3

Noninvasive Option

DSUVIA offers a noninvasive analgesic option when IV access is difficult or delayed, or isn’t otherwise needed.¹

Sublingual Delivery

Sublingual delivery may circumvent the risks associated with IV lines, such as infiltration and phlebitis.^1,4

Prefilled Applicator

A prefilled, single-dose applicator delivers one tablet of DSUVIA, so there’s no leftover drug to waste and witness when accurately administered.^1,5

Single Fixed Dosage

DSUVIA comes in one strength and avoids calculations that can complicate dosing and lead to errors.^1,6

Extended Redosing Interval

DSUVIA showed an average of 3 hours between doses over a 12-hour period, with a minimum redosing interval of 1 hour. Maximum daily dose is 12 tablets.²*^†

Timely Pain Reduction

DSUVIA showed a greater pain intensity difference to baseline vs placebo (P=0.002) based on SPID12 at 15 minutes, the first assessment.²*

*The efficacy and safety of DSUVIA were demonstrated in a pivotal trial of 161 postoperative abdominal surgery patients. The primary endpoint was time-weighted summed pain intensity difference to baseline over 12 hours (SPID12). A secondary endpoint was pain intensity difference to baseline at each evaluation time point. Redosing interval (time between doses) was also recorded.^1,2

^†Patients may require more frequent redosing (minimum interval 1 hour) than the 3-hour average when initiating DSUVIA.¹

Which of your adult patients with acute pain may be right for DSUVIA?

DSUVIA is indicated for use in adults in a certified medically supervised healthcare setting for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.¹

For more information on the uses in this specialty, please refer to the study cited.⁷

The following patient profiles are not based on actual patients. Please use your medical expertise to determine if DSUVIA is right for your patients. All individuals depicted are models used for illustrative purposes only.

ClickTap below to expand patient profiles.Close patient profile to see all selections

Dislocated shoulder with acute pain

Patient needs IV only for analgesia

Ankle sprain/fracture with acute pain

Patient has severe needle phobia

Dislocated shoulder
with acute pain⁷

Patient needs IV only for analgesia

43-year-old female
115 lb (BMI 20)
No relevant medical history
Pain score at triage: 9/10

Physician attempts reduction without analgesia. Patient experiences increased pain and muscle contraction, and attempt fails. Physician orders IV placement for procedural analgesia.

Consider DSUVIA FOR SUBLINGUAL DELIVERY

a noninvasive option.¹

Not an actual patient.

Ankle sprain/fracture
with acute pain⁷

Patient has severe needle phobia

36-year-old male
145 lb (BMI 21)
No relevant medical history
Pain score at triage: 6/10

After physician evaluation, nurse attempts IV cannulation for analgesia while patient waits for
X-ray. Patient shows signs of needle phobia, heart rate drops sharply, and syncope occurs.

Consider DSUVIA FOR SUBLINGUAL DELIVERY

a noninvasive option.¹

Not an actual patient.

Open-label emergency department study

DSUVIA was studied in non-opioid-tolerant patients in the emergency department with pain due to trauma or injury.⁷

see the study

More information on DSUVIA

One Applicator
Is One Dose

Learn about the single-
strength
dosing and
sublingual
administration
of DSUVIA

Pivotal Study
Safety Profile

Read about the most common
adverse reactions with
DSUVIA and see special
precautions

Pivotal Study
Efficacy Data

See how DSUVIA
reduced pain intensity
over 12 hours in the
pivotal trial

Indications and Usage

DSUVIA is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Limitations of Use:

Not for home use or for use in children. Discontinue treatment with DSUVIA before patients leave the certified medically supervised healthcare setting.
Not for use for more than 72 hours. The use of DSUVIA beyond 72 hours has not been studied.
Only to be administered by a healthcare provider.
Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, reserve DSUVIA for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:
- Have not been tolerated, or are not expected to be tolerated,
- Have not provided adequate analgesia, or are not expected to provide adequate analgesia.

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF DSUVIA

Accidental Exposure and DSUVIA Risk Evaluation and Mitigation Strategy (REMS) Program

Accidental exposure to or ingestion of DSUVIA, especially in children, can result in respiratory depression and death. Because of the potential for life-threatening respiratory depression due to accidental exposure, DSUVIA is only available through a restricted program called the DSUVIA REMS Program.

DSUVIA must only be dispensed to patients in a certified medically supervised healthcare setting.
Discontinue use of DSUVIA prior to discharge or transfer from the certified medically supervised healthcare setting.

Addiction, Abuse, and Misuse

Because the use of DSUVIA exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing DSUVIA, and reassess all patients regularly for the development of these behaviors or conditions.

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of DSUVIA. Monitor for respiratory depression, especially during initiation of DSUVIA.

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of DSUVIA and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.

Cytochrome P450 3A4 Interaction

The concomitant use of DSUVIA with all cytochrome P450 3A4 inhibitors may result in an increase in sufentanil plasma concentrations, which could increase or prolong adverse drug reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in sufentanil plasma concentration. Monitor patients receiving DSUVIA and any CYP3A4 inhibitor or inducer.

Contraindications

Use of DSUVIA is contraindicated in patients with:

Significant respiratory depression.
Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment.
Known or suspected gastrointestinal obstruction, including paralytic ileus.
Known hypersensitivity to sufentanil or components of DSUVIA.

Warnings and Precautions

DSUVIA is for use in adult patients only in a certified medically supervised healthcare setting. Use of DSUVIA outside of this setting can increase the risk of accidental exposure in others for whom it is not prescribed, causing fatal respiratory depression. Discontinue use of DSUVIA prior to discharge or transfer from the certified medically supervised healthcare setting. DSUVIA is not for home or pediatric use.
DSUVIA contains sufentanil, a Schedule II controlled substance. As an opioid, DSUVIA exposes users to the risks of addiction, abuse, and misuse.
Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider minimizing the use of DSUVIA and carefully monitor the patient for signs of respiratory depression.
Accidental ingestion or exposure to even one dose of DSUVIA, especially in children, can result in respiratory depression and death due to an overdose of sufentanil.
Profound sedation, respiratory depression, coma, and death may result from the concomitant use of DSUVIA with benzodiazepines or other CNS depressants, including alcohol (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids). Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.
Opioid-Induced Hyperalgesia and Allodynia: Opioid-Induced Hyperalgesia (OIH) occurs when an opioid analgesic paradoxically causes an increase in pain, or an increase in sensitivity to pain. If OIH is suspected, carefully consider appropriately decreasing the dose of the current opioid analgesic, or opioid rotation.
A potentially life-threatening condition could result from concomitant serotonergic drug administration. Discontinue DSUVIA if serotonin syndrome is suspected.
Life-threatening respiratory depression in patients with chronic pulmonary disease or in elderly, cachectic and debilitated patients: monitor patients closely, particularly when initiating DSUVIA therapy and when DSUVIA is used with other drugs that depress respiration. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient’s clinical status.
Cases of adrenal insufficiency have been reported with opioid use (usually > 1 month). Presentation and symptoms are non-specific and include nausea, vomiting, anorexia, fatigue, weakness, dizziness and low blood pressure. Confirm diagnosis with testing as soon as possible and, if confirmed, treat with physiologic replacement of corticosteroids and wean patient from opioid.
As with all opioids, sufentanil may produce bradycardia or hypotension in some patients. Therefore DSUVIA should be used with caution in patients with bradyarrhythmias or hypovolemia.
DSUVIA should not be used in patients who may be particularly susceptible to the intracranial effects of CO₂ retention, such as those with evidence of increased intracranial pressure, impaired consciousness or coma.
Prolonged use of DSUVIA during pregnancy can result in withdrawal in the neonate, which can be life-threatening. Observe newborns for signs of neonatal opioid withdrawal syndrome and manage accordingly. Advise pregnant women using opioids for a prolonged period of this risk and ensure that appropriate treatment will be available.
Insufficient data are available on the use of DSUVIA in patients with severe liver or kidney impairment. DSUVIA should be used with caution in such patients due to the importance of these organs in the metabolism and excretion of sufentanil.

Adverse Reactions

Adverse reactions are described, or described in greater detail, in other sections of the Prescribing Information:

Addiction, Abuse, and Misuse [see Warnings and Precautions (5.3)]
Life-Threatening Respiratory Depression [see Warnings and Precautions (5.4)]
Opioid-Induced Hyperalgesia and Allodynia [see Warnings and Precautions (5.7)]
Adrenal Insufficiency [see Warnings and Precautions (5.10)]
Severe hypotension [see Warnings and Precautions (5.11)]
Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.13)]
Seizures [see Warnings and Precautions (5.14)]
Neonatal Opioid Withdrawal Syndrome [see Warnings and Precautions (5.16)]

The most commonly reported adverse reactions (≥ 2% and higher than placebo) were nausea, headache, vomiting, dizziness, and hypotension.

Medical Information

For medical inquiries or to report an adverse event, other safety-related information or product complaints for a company product, please contact Vertical Pharmaceuticals, LLC at 1-855-925-8476 or [email protected].

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Full Prescribing Information, including BOXED WARNING and Directions for Use.

References:

1. DSUVIA [package insert]. AcelRx Pharmaceuticals, Inc; 2023.
2. Minkowitz HS, Leiman D, Melson T, Singla N, DiDonato KP, Palmer PP. Sufentanil sublingual tablet 30 mcg for the management of pain following abdominal surgery: a randomized, placebo-controlled, phase-3 study. Pain Pract. 2017;17(7):848-858.
3. Fisher DM, Chang P, Wada DR, Dahan A, Palmer PP. Pharmacokinetic properties of a sufentanil sublingual tablet intended to treat acute pain. Anesthesiology. 2018;128(5):943-952.
4. Kagel EM, Rayan GM. Intravenous catheter complications in the hand and forearm. J Trauma. 2004;56(1):123-127.
5. Brummond PW, Chen DF, Churchill WW, et al. ASHP guidelines on preventing diversion of controlled substances. Am J Health-Syst Pharm. 2017;74(5):325-348.
6. Dy SM, Shore AD, Hicks RW, Morlock LL. Medication errors with opioids: results from a national reporting system. J Opioid Manag. 2007;3(4):189-194.
7. Miner JR, Rafique Z, Minkowitz HS, DiDonato KP, Palmer PP. Sufentanil sublingual tablet 30 mcg for moderate-to-severe acute pain in the ED. Am J Emerg Med. 2018;36(6):954-961.

All individuals depicted are models used for illustrative purposes only.

See more safety information ++